Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents. Issue 4 (April 2017)

• Record Type: Journal Article
• Authors: Aurpibul, Linda; Lumbiganon, Pagakrong; Hansudewechakul, Rawiwan; Kanjanavanit, Suparat; Bunupuradah, Torsak; Kosalaraksa, Pope; Taeprasert, Pawinee; Puthanakit, Thanyawee
• Is Part Of: Pediatric infectious disease journal. Volume 36:Issue 4(2017)
• Publication Date: 2017-04
• Subjects: Hepatitis B -- HIV -- tenofovir -- adolescents -- Asia; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000001491
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV–human immunodeficiency virus-coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although hepatitis B surface antigen loss or hepatitis B envelope antigen seroconversion did not occur.